Ischemic stroke patients with prior stroke and diabetes might still be candidates for thrombolytic therapy, researchers report. A new study published in the November 22 issue of Neurology suggests that these patients derive just as much benefit from treatment as those without these conditions… In an accompanying editorial, Bart Demaerschalk, MD, from the Mayo Clinic in Phoenix, Arizona, applauds the researchers for their concerted empirical effort. "There appears to be no justification for the continued restriction of these patients from receiving thrombolytic therapy."

MedScape, by Allison Shelley,  11/28/11

Tags: Mayo Clinic Arizona, Neurology